Definitive Contract 75N91024C00008
Award Date
2/15/24
Potential Completion Date
5/15/25
Potential Value
$355K
Federal Agency
National Cancer Institute
Awardee
Qana Therapeutics Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Austin, TX 78752, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
26
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...
This is a $300,000 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Coordination Pharmaceuticals Inc., a small business. The contract is for the detection, diagnosis, treatment, prevention, and research of pediatric cancers and/or rare cancers. It was awarded under a Small Business Innovation Research (SBIR) Concept Award Program, which is a "Phase 0" pilot program intended to encourage small businesses to develop innovative and...
The National Cancer Institute (NCI) awarded a $353,102 Firm Fixed Price contract to Angstrom Research Inc., a self-certified small disadvantaged business, for a Phase I SBIR (Small Business Innovation Research) Concept Award. The contract, identified as 75N91024C00012, is part of the NCI's SBIR program and is focused on the development of innovative therapeutic technologies, devices, or diagnostics for the treatment, detection, and diagnosis of Pediatric Cancers and/or Rare Cancers. This is a...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services. The $355,000 Firm Fixed Price contract was awarded to Insilicom LLC, a minority-owned and woman-owned small business, to develop a proof-of-concept technology for drug repurposing targeting rare cancers using a large-scale, high-quality biomedical knowledge graph. The original contract opportunity was a...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract to Nomocan Pharmaceuticals LLC, a for-profit limited liability company, for $354,959. The contract is for the development of a therapeutic technology, device, or diagnostic technology to treat, detect, or diagnose pediatric cancers and rare cancers with survival rates below 50%. The contract has a firm fixed-price pricing type...
This is a $300,000.00 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Chimeron Bio Corporation, a small business manufacturer, for PHASE I THERAPEUTIC AWARD: CHIMERIC NANOPARTICLE DELIVERY OF AN SARNA-BASED CANCER VACCINE FOR FAMILIAL ADENOMATOUS POLYPOSIS under the Small Business Innovation Research (SBIR) Program. The contract is set aside for small businesses. This award is associated with a pre-solicitation opportunity that sought proposals...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Targagenix, Inc. for R&D on a nanoemulsion formulation and IND-enabling studies of a novel cancer stem cell cytotoxic agent. The definitive, firm-fixed-price contract has a ceiling value of $2,284,577.00 and a period of performance ending on October 15, 2018. As an SBIR Phase I award, this contract supports early-stage research and development...
<p>This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency of the U.S. government. The contract, valued at $1,499,398.79, was awarded to Siamab Therapeutics, Inc. to develop novel therapeutic agents that target cancer stem cells, as described in SBIR Topic 326. The contract has a period of performance through September 18, 2018 and is a Cost Plus Fixed Fee definitive contract.</p>
The National Cancer Institute awarded Nzumbe Inc. a $355,000 firm fixed price definitive contract under the Small Business Innovation Research Concept Award program. This program seeks proposals from small businesses for innovative concepts to advance pediatric and rare cancer therapies, diagnostics, or preventatives. Specifically, Nzumbe will demonstrate technical feasibility and proof-of-concept for a highly innovative pediatric or rare cancer idea through preliminary experiments, while also...
This is a Phase I SBIR contract award from the National Cancer Institute (NCI) to Tranquility Biodesign LLC, a small business, for the development of a novel engineered bacterial anticancer immunotherapy for Merkel cell carcinoma. The contract, valued at $354,996.00, was awarded under a total small business set-aside solicitation seeking proposals for the development of therapeutic, device, or diagnostic technologies for the treatment, detection, and diagnosis of pediatric cancers and rare...